Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:08:49.394Z.
Consensus retrieved: 2026-10-06T14:38:31.693Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:08:49.394Z.
Quote observation: 2026-10-06T18:05:27.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 869efbf6e11e98c8b36b953a9b631e7639c239a9e2012f11ad9cca4b0e6b7a7d
Forward PE Ratio (N/A) = Dated Quote Price ($4.41) / Consensus Forward EPS ($-0.36)
FORWARD PE RATIO
N/A
OmniAb, Inc.
Market Cap
$638.60M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| OmniAb, Inc. (OABI) | $638.60M | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $634.98M | N/A |
| SOPHiA GENETICS S.A. (SOPH)vs › | $633.41M | N/A |
| Prime Medicine, Inc. (PRME)vs › | $627.97M | N/A |
| Starling Oncology, Inc. (STLN)vs › | $657.49M | N/A |
| Climb Bio, Inc. (CLYM)vs › | $616.15M | N/A |
| Annexon, Inc. (ANNX)vs › | $664.38M | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $666.85M | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $667.06M | N/A |
| Helus Pharma Inc. (HELP)vs › | $670.59M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $4.41, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.36 | $-0.37 – $-0.35 | 4 | n/m |
| 2027-12-31 | $-0.28 | $-0.33 – $-0.23 | 3 | n/m |
| 2028-12-31 | $-0.10 | $-0.25 – $-0.03 | 4 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
